Navigation Links
Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit
Date:5/25/2010

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics.

Minneapolis, MN (PRWEB) May 25, 2010 -- The Agenda for Arrowhead’s 4th Annual Pain Therapeutics Summit, set to take place on October 4th-5th, 2010 in Philadelphia, has been announced.

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics, regulatory issues, commercialization of new pain therapies and various other topics integral to the field of pain therapeutics.

Topics covered at this year’s Summit include:

Regulatory hurdles in pain drug development
Animal models for pain drug discovery research
Clinical development models
Trial Designs
Abuse-deterrent opioids
Long-term opioid use
Next generation therapeutics for pain
Trends in pain drug development
Preclinical and clinical activity in pain space
FDA Update
Market direction of the field of pain therapeutics
Translational pain research
Competitive landscape
Mixing basic science, drug development and clinical practice
Discovery targets: TRPV, TRPA, TRPM8, NGF antagonists, Nav1.7, P2X4, P2X7
Abuse liability and safety (REMS)
Novel mechanisms of action for future pain therapies

Speakers at this year’s event include:

Jeffrey S. Mogil, Ph.D., E.P. Taylor Chair in Pain Studies, Canada Research Chair in Genetics of Pain, McGill University

William K. Schmidt, Ph.D., Vice President, CG Pharmaceuticals

Theodore Cicero, Ph.D., Professor of Psychiatry, Anatomy & Neurobiology, Washington University in St. Louis
David Hewitt, MD, Senior Director, Clinical Neuroscience, Merck & Co.

Gary W. Jay, MD, DAAPM, FAAPM, Senior Director, Clinical Disease Area Expert - Pain, Pfizer, Inc.

Lynn R. Webster, MD, FACPM, FASAM, Medical Director and Founder, Lifetree Clinical Research & Pain Clinic, Director-At-Large, American Academy of Pain Medicine

Dr. Luca Benatti, CEO, Newron

Andy Billinton, Ph.D., Behavioral and Translational Pharmacology Leader, Pain, Neurosciences, GlaxoSmithKline

Jennifer Bolen, JD, Founder, The Legal Side of Pain (A division of the J. Bolen Group, LLC)

Michael Gold, Ph.D., Associate Professor, Anesthesiology, University of Pittsburgh

James R. Gorman, MD, Ph.D., CEO and Chief Medical Officer, BioAssets Development Corporation

Hyungsuk Kim, DDS, Ph.D, Staff Scientist, NINR, National Institutes of Health

Jennifer Laird, Ph.D., Senior Principal Scientist, AstraZeneca R&D

Frédérique Menzaghi, Ph.D., Vice President Research & Development, Cara Therapeutics

Patricia Richards, MD, Ph.D., Chief Medical Officer, QRx Pharma

For the complete list of speakers as well as the agenda, please visit www.paintherapeuticsummit.com or call 1-312-244-3703.

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4041724.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. FASEB Encourages NIGMS to Broaden Scientific Training Opportunities
2. Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline
3. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
4. Scientific breakthrough in genetic studies of animal domestication
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents
7. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
8. Boston Scientific Announces Completion of $2 Billion Senior Notes Offering
9. Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum
10. Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
11. Advanced Cell Technologys Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the 3rd International Conference on Cell Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... 1, 2017  Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or ... to the life sciences industry, today announced the launch ... reproductive health market. CryoStork SM Next Flight Out ... for reproductive health patients, providing express transportation across ... for reproductive health commodities such as sperm, eggs, embryos ...
(Date:3/1/2017)... SHANGHAI , March 1, 2017 ... Cork based Biotechnology Company and HD ... discovery Contract Research Organization (CRO), announced today that ... and provide new assay technologies for preclinical drug ... access to Luxcel,s state-of-the-art assays and technologies for ...
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... ... , ... Surface Plasmon Resonance (SPR) is a widely-used, label-free technique to characterize ... changes in the dielectric properties of the medium close to a metal surface. ... to 300 nm above the metal surface (Au) and thus by the material absorbed ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):